Advanced Glycation End Products and Diabetic Complications

Overview

Journal Korean J Physiol Pharmacol

Specialty Pharmacology

Date 2014 Mar 18

PMID 24634591

Citations 501

Authors

Varun Parkash Singh

Anjana Bali

Nirmal Singh

Amteshwar Singh Jaggi

Affiliations

Soon will be listed here.

Abstract

During long standing hyperglycaemic state in diabetes mellitus, glucose forms covalent adducts with the plasma proteins through a non-enzymatic process known as glycation. Protein glycation and formation of advanced glycation end products (AGEs) play an important role in the pathogenesis of diabetic complications like retinopathy, nephropathy, neuropathy, cardiomyopathy along with some other diseases such as rheumatoid arthritis, osteoporosis and aging. Glycation of proteins interferes with their normal functions by disrupting molecular conformation, altering enzymatic activity, and interfering with receptor functioning. AGEs form intra- and extracellular cross linking not only with proteins, but with some other endogenous key molecules including lipids and nucleic acids to contribute in the development of diabetic complications. Recent studies suggest that AGEs interact with plasma membrane localized receptors for AGEs (RAGE) to alter intracellular signaling, gene expression, release of pro-inflammatory molecules and free radicals. The present review discusses the glycation of plasma proteins such as albumin, fibrinogen, globulins and collagen to form different types of AGEs. Furthermore, the role of AGEs in the pathogenesis of diabetic complications including retinopathy, cataract, neuropathy, nephropathy and cardiomyopathy is also discussed.

Citing Articles

Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities.

Pandey A, Alcaraz Jr M, Saggese P, Soto A, Gomez E, Jaldu S Cancers (Basel). 2025; 17(3).

PMID: 39941833 PMC: 11815934. DOI: 10.3390/cancers17030466.

Deciphering the Association: Critical HDL-C Levels and Their Impact on the Glycation Gap in People Living with HIV.

Anaya-Ambriz E, Alvarez-Zavala M, Gonzalez-Hernandez L, Andrade-Villanueva J, Zuniga-Quinones S, Valle-Rodriguez A Int J Mol Sci. 2025; 26(3).

PMID: 39940683 PMC: 11817432. DOI: 10.3390/ijms26030914.

A Comparative Study of Nanoconjugates of a Synthetic and a Natural Drug Against T2DM-Induced Cognitive Dysfunction.

Pradhan S, Behera A, Sahu P J Neuroimmune Pharmacol. 2025; 20(1):11.

PMID: 39893302 DOI: 10.1007/s11481-025-10170-0.

Advances of research in diabetic cardiomyopathy: diagnosis and the emerging application of sequencing.

He Q, Lai Z, Zhai Z, Zou B, Shi Y, Feng C Front Cardiovasc Med. 2025; 11:1501735.

PMID: 39872882 PMC: 11769946. DOI: 10.3389/fcvm.2024.1501735.

Oxidative Stress, Glutathione Insufficiency, and Inflammatory Pathways in Type 2 Diabetes Mellitus: Implications for Therapeutic Interventions.

Dawi J, Misakyan Y, Affa S, Kades S, Narasimhan A, Hajjar F Biomedicines. 2025; 13(1).

PMID: 39857603 PMC: 11762874. DOI: 10.3390/biomedicines13010018.

References

Vlassara H, Brownlee M, Cerami A . Nonenzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proc Natl Acad Sci U S A. 1981; 78(8):5190-2. PMC: 320369. DOI: 10.1073/pnas.78.8.5190. View

Elseweidy M, Elswefy S, Younis N, Zaghloul M . Pyridoxamine, an inhibitor of protein glycation, in relation to microalbuminuria and proinflammatory cytokines in experimental diabetic nephropathy. Exp Biol Med (Maywood). 2013; 238(8):881-8. DOI: 10.1177/1535370213494644. View

Franke S, Dawczynski J, Strobel J, Niwa T, Stahl P, Stein G . Increased levels of advanced glycation end products in human cataractous lenses. J Cataract Refract Surg. 2003; 29(5):998-1004. DOI: 10.1016/s0886-3350(02)01841-2. View

Nicholl I, Stitt A, Moore J, Ritchie A, Archer D, Bucala R . Increased levels of advanced glycation endproducts in the lenses and blood vessels of cigarette smokers. Mol Med. 1998; 4(9):594-601. PMC: 2230315. View

Joussen A, Poulaki V, Mitsiades N, Cai W, Suzuma I, Pak J . Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J. 2002; 17(1):76-8. DOI: 10.1096/fj.02-0157fje. View

Vasan S, Foiles P, Founds H . Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys. 2003; 419(1):89-96. DOI: 10.1016/j.abb.2003.08.016. View

Twigg S, Cao Z, MCLennan S, Burns W, Brammar G, Forbes J . Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology. 2002; 143(12):4907-15. DOI: 10.1210/en.2002-220619. View

Ihm S, Chang K, Kim H, Baek S, Youn H, Seung K . Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth.... Basic Res Cardiol. 2009; 105(3):399-407. DOI: 10.1007/s00395-009-0071-x. View

Hashim Z, Zarina S . Advanced glycation end products in diabetic and non-diabetic human subjects suffering from cataract. Age (Dordr). 2010; 33(3):377-84. PMC: 3168597. DOI: 10.1007/s11357-010-9177-1. View

10.

Titov V, Khokhlova N, Shiriaeva I . [Glucose, glycotoxins, and protein glycation products: the role in pathogensis]. Klin Med (Mosk). 2013; 91(3):15-24. View

11.

Jorneskog G, Hansson L, Wallen N, Yngen M, Blomback M . Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost. 2003; 1(6):1195-201. DOI: 10.1046/j.1538-7836.2003.00301.x. View

12.

Caldwell R, Bartoli M, Behzadian M, El-Remessy A, Al-Shabrawey M, Platt D . Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003; 19(6):442-55. DOI: 10.1002/dmrr.415. View

13.

Vlassara H, Li Y, Imani F, Wojciechowicz D, Yang Z, Liu F . Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med. 1995; 1(6):634-46. PMC: 2229987. View

14.

Bork P, Holm L, Sander C . The immunoglobulin fold. Structural classification, sequence patterns and common core. J Mol Biol. 1994; 242(4):309-20. DOI: 10.1006/jmbi.1994.1582. View

15.

Chibber R, Molinatti P, Rosatto N, Lambourne B, Kohner E . Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia. 1997; 40(2):156-64. DOI: 10.1007/s001250050657. View

16.

Kawai T, Takei I, Tokui M, Funae O, Miyamoto K, Tabata M . Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine. J Diabetes Complications. 2009; 24(6):424-32. DOI: 10.1016/j.jdiacomp.2008.10.005. View

17.

Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M . Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001; 108(2):261-8. PMC: 203021. DOI: 10.1172/JCI11771. View

18.

Ookawara T, Kawamura N, Kitagawa Y, Taniguchi N . Site-specific and random fragmentation of Cu,Zn-superoxide dismutase by glycation reaction. Implication of reactive oxygen species. J Biol Chem. 1992; 267(26):18505-10. View

19.

Nakamura N, Hasegawa G, Obayashi H, Yamazaki M, Ogata M, Nakano K . Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2003; 61(2):93-101. DOI: 10.1016/s0168-8227(03)00109-8. View

20.

El-Mesallamy H, Hamdy N, Ezzat O, Reda A . Levels of soluble advanced glycation end product-receptors and other soluble serum markers as indicators of diabetic neuropathy in the foot. J Investig Med. 2011; 59(8):1233-8. DOI: 10.2130/JIM.0b013e318231db64. View